首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1701413

眼科藥物市場規模、佔有率、成長分析（按疾病、藥物類別、劑量、給藥方式、產品和地區）－2025 年至 2032 年產業預測

Ophthalmic Drugs Market Size, Share, and Growth Analysis, By Disease (Eye Allergy, Eye Infection), By Drug Class (Anti-Allergy, Anti-Inflammatory), By Dosage, By Administration, By Product, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月02日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年眼科藥物市場規模價值 346 億美元，預計將從 2024 年的 366.1 億美元成長到 2032 年的 574.7 億美元，預計在預測期內（2025-2032 年）的複合年成長率為 5.8%。

由於產業領導者加強研發創新治療方法和策略措施的力度，眼科藥物市場預計將經歷顯著成長。全球約有22億人患有視力障礙，其中大部分是可以預防的，因此市場潛力巨大。與老齡化相關的視力問題是一個主要促成因素，並造成沉重的經濟負擔，僅近視一項就造成約 2,440 億美元的經濟損失。 COVID-19 疫情導致眼科服務下降，但由於疫苗供應增加，市場預計將復甦。像愛爾康這樣的公司正在加大對研發的投資，策略性收購和 FDA核准使公司能夠利用這一成長機會，確保眼科領域的強勁未來。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Novartis AG（Switzerland）
Johnson & Johnson Vision（United States）
Alcon Inc.（Switzerland）
AbbVie Inc.（United States）
Bausch Health Companies Inc.（Canada）
Regeneron Pharmaceuticals Inc.（United States）
Pfizer Inc.（United States）
Santen Pharmaceutical Co. Ltd.（Japan）
Merck & Co., Inc.（United States）
Bayer AG（Germany）
Coherus Biosciences, Inc.（United States）
Genentech, Inc.（United States）
Sun Pharmaceutical Industries Ltd.（India）
Aerie Pharmaceuticals（United States）
Rohto Pharmaceutical Co., Ltd.（Japan）
Menicon Co., Ltd.（Japan）
Ellex Medical Lasers Ltd.（Australia）
Topcon Corporation（Japan）
Veeva Systems Inc.（United States）
Recipharm AB（Sweden）

結論和建議

簡介目錄

Product Code: SQMIG35I2222

Ophthalmic Drugs Market size was valued at USD 34.6 billion in 2023 and is poised to grow from USD 36.61 billion in 2024 to USD 57.47 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The ophthalmic drugs market is poised for significant growth driven by intensified research and development efforts to create innovative treatments and strategic initiatives from industry leaders. With around 2.2 billion people globally experiencing vision impairment, many cases being preventable, the market's potential is vast. Age-related vision issues are the primary driver, contributing to a substantial economic burden, such as the estimated USD 244 billion cost linked to myopia alone. Although the COVID-19 pandemic caused a decline in ophthalmic services, the market is expected to rebound due to increased vaccine availability. Companies like Alcon are ramping up R&D investments, and strategic acquisitions and FDA approvals are further positioning firms to capitalize on this growth opportunity, ensuring a robust future for ophthalmic therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Drugs Market Segments Analysis

Global Ophthalmic Drugs Market is segmented by Disease, Drug Class, Dosage, Administration, Product and region. Based on Disease, the market is segmented into Eye Allergy, Eye Infection, Glaucoma, Retinal Disorders, Dry Eye and Others. Based on Drug Class, the market is segmented into Anti-Allergy, Anti-Inflammatory, Antiglaucoma and Anti-VEGF Agents. Based on Dosage, the market is segmented into Eye Solutions, Gels, Capsules, Eye Drops and Ointments. Based on Administration, the market is segmented into Systematic, Topical and Local Ocular. Based on Product, the market is segmented into Prescription Drugs and Over-the-Counter-Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Drugs Market

The ophthalmic drugs market is predominantly driven by the increasing prevalence of various eye conditions, including cataracts, glaucoma, and macular degeneration. This surge can be attributed to several factors, such as the aging population, shifts in lifestyle habits, and a rise in chronic illnesses. As more individuals experience these eye-related issues, the demand for effective ophthalmic medications is escalating. Consequently, this trend is fostering growth within the market as healthcare providers and pharmaceutical companies focus on developing and delivering innovative treatments to meet the needs of patients affected by these prevalent eye diseases.

Restraints in the Ophthalmic Drugs Market

The ophthalmic drugs market faces a significant restraint due to stringent regulatory requirements governing drug approval and market entry. These complex and often protracted regulatory procedures create hurdles for companies, leading to delays in product launches and potentially stifling market growth. As manufacturers strive to navigate these rigorous guidelines, the extended timelines and increased costs associated with compliance can impede their ability to bring innovative treatments to market efficiently. Consequently, the challenges linked to regulatory scrutiny can act as deterrents, affecting overall competitiveness and limiting opportunities within the ophthalmic drugs sector.

Market Trends of the Ophthalmic Drugs Market

The ophthalmic drugs market is increasingly leaning towards personalized medicine, a trend driven by the need for treatments that cater to individual patient profiles and unique ocular conditions. With advancements in genomic research and the rise of precision medicine, pharmaceutical companies are developing targeted therapies that enhance therapeutic efficacy and boost patient satisfaction. This shift not only improves clinical outcomes but also fosters a more patient-centric approach in ophthalmology. As regulatory bodies adapt to these innovations, the market is expected to see a surge in the adoption of customized treatment plans that align with the characteristics of specific patient populations, further transforming the landscape of eye care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies

Global Ophthalmic Drugs Market Size by Disease & CAGR (2025-2032)

Market Overview
Eye Allergy
Eye Infection
Glaucoma
Retinal Disorders
Dry Eye
Others

Global Ophthalmic Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Anti-Allergy
Anti-Inflammatory
Antiglaucoma
Anti-VEGF Agents

Global Ophthalmic Drugs Market Size by Dosage & CAGR (2025-2032)

Market Overview
Eye Solutions
Gels
Capsules
Eye Drops
Ointments

Global Ophthalmic Drugs Market Size by Administration & CAGR (2025-2032)

Market Overview
Systematic
Topical
Local Ocular

Global Ophthalmic Drugs Market Size by Product & CAGR (2025-2032)

Market Overview
Prescription Drugs
Over-the-Counter-Drugs

Global Ophthalmic Drugs Market Size & CAGR (2025-2032)

North America (Disease, Drug Class, Dosage, Administration, Product)
- US
- Canada
Europe (Disease, Drug Class, Dosage, Administration, Product)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease, Drug Class, Dosage, Administration, Product)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease, Drug Class, Dosage, Administration, Product)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease, Drug Class, Dosage, Administration, Product)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Vision (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus Biosciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aerie Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rohto Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menicon Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ellex Medical Lasers Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Topcon Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veeva Systems Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments